Market closed

Castle Biosciences/$CSTL

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Castle Biosciences

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

Ticker

$CSTL
Trading on

Industry

Health Care Providers & Services

Employees

710

CSTL Metrics

BasicAdvanced
$771M
Market cap
130.87
P/E ratio
$0.21
EPS
0.98
Beta
-
Dividend rate
$771M
0.98
$33.33
$16.97
342K
7.784
7.451
5.667
6.063
-2.13%
-0.14%
1.47%
130.867
2.428
1.75
2.33
21.923
62.43%
-107.42%
53.43%
-44.64%

What the Analysts think about CSTL

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Castle Biosciences stock.

CSTL Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CSTL Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CSTL

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Castle Biosciences stock?

Castle Biosciences (CSTL) has a market cap of $771M as of December 22, 2024.

What is the P/E ratio for Castle Biosciences stock?

The price to earnings (P/E) ratio for Castle Biosciences (CSTL) stock is 130.87 as of December 22, 2024.

Does Castle Biosciences stock pay dividends?

No, Castle Biosciences (CSTL) stock does not pay dividends to its shareholders as of December 22, 2024.

When is the next Castle Biosciences dividend payment date?

Castle Biosciences (CSTL) stock does not pay dividends to its shareholders.

What is the beta indicator for Castle Biosciences?

Castle Biosciences (CSTL) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.